Passage Bio
PASG
58 hedge funds and large institutions have $34M invested in Passage Bio in 2023 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 15 increasing their positions, 15 reducing their positions, and 14 closing their positions.
100% more call options, than puts
Call options by funds: $2K | Put options by funds: $1K
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 15
0.17% less ownership
Funds ownership: 3.43% → 3.25% (-0.17%)
13% less funds holding
Funds holding: 67 → 58 (-9)
34% less capital invested
Capital invested by funds: $51.5M → $34M (-$17.5M)
64% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$407K |
| 2 |
Morgan Stanley
New York
|
+$317K |
| 3 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
+$70K |
| 4 |
Vontobel Holding
Zurich,
Switzerland
|
+$61K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$31.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$1.13M |
| 2 |
OMC
Oasis Management Company
Grand Cayman,
Cayman Islands
|
-$331K |
| 3 |
Renaissance Technologies
New York
|
-$307K |
| 4 |
Millennium Management
New York
|
-$259K |
| 5 |
NYLIM
New York Life Investment Management
New York
|
-$253K |
PASG Hedge Fund Activity: Q1 2023 in Review
58 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Passage Bio (PASG) for Q1 2023, worth a combined $34M — down 34% from $51.5M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of PASG and 5 opened new positions — a net loss of 9 holders — while 15 trimmed existing stakes and 15 added.
The largest buyer was Tang Capital Management, opening a new position worth an estimated $407K. The largest seller was Rubric Capital Management (New York), exiting entirely with an estimated $1.13M sold.
- 58 institutional investors held Passage Bio (PASG) as of Q1 2023, down from 67 in Q4 2022.
- Funds reported $34M of Passage Bio stock for Q1 2023, down 34% quarter-over-quarter.
- 5 funds opened new Passage Bio positions in Q1 2023 and 14 closed out, a net change of -9 holders.
- The largest Passage Bio buyer in Q1 2023 was Tang Capital Management, an estimated $407K added.
- The largest Passage Bio seller in Q1 2023 was Rubric Capital Management (New York), an estimated $1.13M sold.
Based on aggregated 13F filings for Q1 2023.